Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for ORKA-001 (IL-23p19 Antibody) in Psoriasis. The expected timing is based on the latest available company guidance and may change.
11/12/25:- EVERLAST-B Ph2b psoriasis trial planned to initiate H1 2026, evaluating three dose levels versus placebo. 01/12/26:- EVERLAST-B Ph2b first patients dosed December 2025; enrollment ongoing with PASI 100 Week16 primary endpoint and data in 2027. 03/12/26:- EVERLAST-B enrollment ongoing; multiple induction regimens, PASI 100 Week16; data in 2027 to support Ph3. 05/13/26:- EVERLAST-B Ph2b progressing with NA/EU sites active; initial Week16 data expected 2027 to support Ph3. 08/10/26:- EVERLAST-B fully enrolled. Week16 data expected Q4 2026. Phase3 starts H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.